Holiday Health Segment features Biotechnology product from UV Flu
Technologies (OTCBB: UVFT)
Point Roberts, WA, LINCOLNSHIRE, Ill –November 16, 2010 (Investorideas.com Newswire)
Investorideas.com reports that showcase biotech stock UV Flu Technologies (OTC.BB: UVFT)
is the “Star of the Show “on the Designing Spaces, Holiday Spaces – ‘Innovations for a Healthy
Home this Holiday Season’ segment.
Designing Spaces host Debi Marie interviews J. Lennon, President and CEO of UV Flu
Technologies (OTCBB: UVFT), along with pediatrician Dr. Dennis J. Rosen. The segment
discusses how UV Flu Technologies lead product, UV-400 Air Purifier, is an added and important
health measure to keep holiday colds and flu’s out of the house during the busy social season.
Interested investors and consumers can watch the UV Flu Technologies segment on
Designing Spaces at http://www.designingspaces.tv/show_segment.php?id=732 or at
the company’s website http://www.uvflutech.com/
During the holidays, families and friends look forward to spending time together. The one thing
they might not look forward to is that along with the company, you may be inviting unwelcomed
cold and flu germs as well! UV FLU Technologies, Inc. offers an innovative way to help deter the
unwanted holiday bugs. More: http://www.designingspaces.tv/show_segment.php?id=732
About UVFT.OB: UV Flu Technologies, Inc. (OTCBB: UVFT) is an innovative developer,
manufacturer and distributor of bio technology products initially targeting the rapidly growing
Indoor Air Quality ("IAQ") industry sector. The Company manufactures the ViraTech UV-400,
which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that
goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-
pass basis. VIRATECH UV-400 is a Class II medical device and is available
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Get added to the company’s news alerts :
http://www.investorideas.com/Resources/Newsletter.asp
UV Flu Technologies (OTC.BB: UVFT) recent news;
Biotech/Pharma Stocks News; UV Flu Technologies (OTCBB: UVFT) Announces UV-400
Air Purifier Delivers Favorable Preliminary Test Results for the Inactivation of Viruses
CENTERVILLE, MA – November 11, 2010 (Investorideas.com Newswire) - UV Flu Technologies,
Inc. (OTCBB: UVFT) (the "Company") is pleased to announce that the Company has received
favorable preliminary test results from an independent, FDA and EPA certified test facility that
demonstrated the ViraTech UV-400 air purifier to be effective in the inactivation of a typical virus
surrogate utilized as part of the test protocol.
"These results, although preliminary, are highly encouraging," said Jack Lennon, President of
UV Flu Technologies. "The viral phage was tested multiple times, with the UV-400 running at
three different speeds; low, medium and high, over a four hour period in a 430 cubic foot test
chamber. After three hours, the chamber showed a sample inactivation rate of at least 99% over
all three speeds, which was shown to be even higher at the four hour mark. We must emphasize
that these results, although very positive, are only preliminary, but appear comparable to our
previous results during the laboratory testing of the inactivation of bacteria. Our Company is
firmly committed to supporting all claims with actual, verifiable laboratory testing undertaken by
reputable agencies within certified facilities."
Full News at: http://www.investorideas.com/CO/UVFT/news/11111.asp
Contact UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
Research more biotech stocks at the Biotech stocks Directory: http://
www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized
in sector investing, covering leading industry sectors including mining and gold stocks, in addition
to global markets including China, India, the Middle East and Australia. Investorideas.com is
known for its comprehensive stock directories in each sector and sector specific newswires.
About our Biotech investor portal: www.biotechindustrystocks.com
BiotechIndustryStocks.com is a global meeting place for investors and industry following the
sector, within Investorideas.com. Global visitors use the site daily to research the latest news,
articles, audio, research reports and our stock directories.
Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc., (three thousand per
month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations,
but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured
companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Contact Investorideas.com
cvanzant@investorideas.com 800 665 0411
Tuesday, November 16, 2010
Investor Video Airing for BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) November 20th
BioSante Pharmaceutical’s President and CEO to be featured on WallStreetCast
on ‘Fox Business with Steve Crowley’, Saturday at 1 pm EST
Point Roberts, WA, LINCOLNSHIRE, Ill –November 16, 2010 (Investorideas.com Newswire)
Investorideas.com announces to interested biotech and pharmaceutical investors following
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) that the company will be featured in an
upcoming video segment November 20th.
Saturdays airing will feature Mr. Stephen Simes, President and CEO of BioSante, discussing
BioSante’s lead products, including LibiGel®, with host Steve Crowley.
For interested investors looking to watch BioSante’s segment, the show will be aired on
WallStreetCast on Fox Business on Saturday, November 20th at 1 PM EST
Investors can also go to the Money Channel at, http://www.moneychannel.tv/ to find times aired
and to learn more about Steve Crowley and his interviews with top companies.
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) was also recently interviewed on
Investorideas.com in a Q&A format. Stephen M. Simes, President and CEO of BPAX Discusses
LibiGel (Testosterone Gel) in Phase III and GVAX Pancreas Vaccine in Phase II. The transcript is
available in full at: http://www.investorideas.com/CO/BPAX/news/11051.asp.
The company was also featured in a recent Investor Spotlight on Investordieas.com and its
syndicated partner sites:
BioSante Pharmaceuticals (NASDAQ: BPAX) Lead Product LibiGel® - testosterone gel for
the treatment of female sexual dysfunction
Market for LibiGel® has wide potential with predictions ranging from about $2.0 billion up to $5
billion
Point Roberts, WA, LINCOLNSHIRE, Ill - November 9, 2010 (Investorideas.com Newswire,)
Investor ideas and its biotech portal present a company and product spotlight for BioSante
Pharmaceuticals, Inc. (NASDAQ: BPAX) lead product LibiGel®.
Investors following biotech and pharmaceutical stocks can take an in-depth look at the current
status of LibiGel®, the clinical data, the market drivers and opportunities within the company
product brochure, recent news links and a recent Q&A with Mr. Stephen M. Simes, President and
CEO discussing LibiGel.
Highlights from the LibiGel Brochure:
Read the Full Brochure at: http://www.biosantepharma.com/libigel/LibiGel-Brochure.pdf
LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who
suffer from female sexual dysfunction (FSD). The on-going Phase III efficacy trials are double-
blind, placebo-controlled trials that will enroll up to approximately 500 surgically menopausal
women each for a six-month clinical trial. The efficacy trials are being conducted under an FDA-
approved special protocol assessment (SPA) agreement. LibiGel is absorbed quickly through
the skin after applying a once-daily pea-sized topical application on the upper arm that delivers
testosterone to the bloodstream evenly over time.
Full Article: http://www.investorideas.com/CO/BPAX/news/11101.asp
Research more biotech stocks at the Biotech stocks Directory: http://
www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized
in sector investing, covering leading industry sectors including mining and gold stocks, in addition
to global markets including China, India, the Middle East and Australia. Investorideas.com is
known for its comprehensive stock directories in each sector and sector specific newswires.
About our Biotech investor portal: www.biotechindustrystocks.com
BiotechIndustryStocks.com is a global meeting place for investors and industry following the
sector, within Investorideas.com. Global visitors use the site daily to research the latest news,
articles, audio, research reports and our stock directories.
If you have any questions regarding information in this press release please contact the company
listed in the press release.
Contact BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
The content from the investor Fact sheet and opinions from http://
www.biosantepharma.com/downloads/BioSante-Fact-Sheet.pdf are not the opinion of
Investorideas.com or related websites.
Disclaimer:
The following news is paid for by BPAX (three thousand per month) Investorideas.com is a
third party publisher of news and research .Our sites do not make recommendations, but offer
information portals to research news, articles, stock lists and recent research. Nothing on our
sites should be construed as an offer or solicitation to buy or sell products or securities. This site
is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Source: Investorideas.com, BioSante, Investorideas.com
Contact Investorideas.com to become a biotech showcase stock or research biotech stocks
800 665 0411 cvanzant@investorideas.com
on ‘Fox Business with Steve Crowley’, Saturday at 1 pm EST
Point Roberts, WA, LINCOLNSHIRE, Ill –November 16, 2010 (Investorideas.com Newswire)
Investorideas.com announces to interested biotech and pharmaceutical investors following
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) that the company will be featured in an
upcoming video segment November 20th.
Saturdays airing will feature Mr. Stephen Simes, President and CEO of BioSante, discussing
BioSante’s lead products, including LibiGel®, with host Steve Crowley.
For interested investors looking to watch BioSante’s segment, the show will be aired on
WallStreetCast on Fox Business on Saturday, November 20th at 1 PM EST
Investors can also go to the Money Channel at, http://www.moneychannel.tv/ to find times aired
and to learn more about Steve Crowley and his interviews with top companies.
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) was also recently interviewed on
Investorideas.com in a Q&A format. Stephen M. Simes, President and CEO of BPAX Discusses
LibiGel (Testosterone Gel) in Phase III and GVAX Pancreas Vaccine in Phase II. The transcript is
available in full at: http://www.investorideas.com/CO/BPAX/news/11051.asp.
The company was also featured in a recent Investor Spotlight on Investordieas.com and its
syndicated partner sites:
BioSante Pharmaceuticals (NASDAQ: BPAX) Lead Product LibiGel® - testosterone gel for
the treatment of female sexual dysfunction
Market for LibiGel® has wide potential with predictions ranging from about $2.0 billion up to $5
billion
Point Roberts, WA, LINCOLNSHIRE, Ill - November 9, 2010 (Investorideas.com Newswire,)
Investor ideas and its biotech portal present a company and product spotlight for BioSante
Pharmaceuticals, Inc. (NASDAQ: BPAX) lead product LibiGel®.
Investors following biotech and pharmaceutical stocks can take an in-depth look at the current
status of LibiGel®, the clinical data, the market drivers and opportunities within the company
product brochure, recent news links and a recent Q&A with Mr. Stephen M. Simes, President and
CEO discussing LibiGel.
Highlights from the LibiGel Brochure:
Read the Full Brochure at: http://www.biosantepharma.com/libigel/LibiGel-Brochure.pdf
LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who
suffer from female sexual dysfunction (FSD). The on-going Phase III efficacy trials are double-
blind, placebo-controlled trials that will enroll up to approximately 500 surgically menopausal
women each for a six-month clinical trial. The efficacy trials are being conducted under an FDA-
approved special protocol assessment (SPA) agreement. LibiGel is absorbed quickly through
the skin after applying a once-daily pea-sized topical application on the upper arm that delivers
testosterone to the bloodstream evenly over time.
Full Article: http://www.investorideas.com/CO/BPAX/news/11101.asp
Research more biotech stocks at the Biotech stocks Directory: http://
www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized
in sector investing, covering leading industry sectors including mining and gold stocks, in addition
to global markets including China, India, the Middle East and Australia. Investorideas.com is
known for its comprehensive stock directories in each sector and sector specific newswires.
About our Biotech investor portal: www.biotechindustrystocks.com
BiotechIndustryStocks.com is a global meeting place for investors and industry following the
sector, within Investorideas.com. Global visitors use the site daily to research the latest news,
articles, audio, research reports and our stock directories.
If you have any questions regarding information in this press release please contact the company
listed in the press release.
Contact BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
The content from the investor Fact sheet and opinions from http://
www.biosantepharma.com/downloads/BioSante-Fact-Sheet.pdf are not the opinion of
Investorideas.com or related websites.
Disclaimer:
The following news is paid for by BPAX (three thousand per month) Investorideas.com is a
third party publisher of news and research .Our sites do not make recommendations, but offer
information portals to research news, articles, stock lists and recent research. Nothing on our
sites should be construed as an offer or solicitation to buy or sell products or securities. This site
is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Source: Investorideas.com, BioSante, Investorideas.com
Contact Investorideas.com to become a biotech showcase stock or research biotech stocks
800 665 0411 cvanzant@investorideas.com
Monday, November 15, 2010
Biotech/Pharma Stock News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Reports Third Quarter 2010 Financial Results
LINCOLNSHIRE, Ill. - November 15, 2010 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced its third quarter 2010 financial results.
BioSante incurred a net loss of approximately $11.6 million or ($0.16) per share for the quarter ended September 30, 2010, compared to a net loss of $6.4 million or ($0.21) per share for the same period in 2009. This increase in net loss was primarily due to increased LibiGel clinical development expenses.
The Company's cash and cash equivalents as of September 30, 2010 were approximately $35.5 million, as compared to cash and cash equivalents of approximately $29.9 million on December 31, 2009. In October 2010, the Company received $244,479, the maximum per project, after LibiGel qualified for a grant under the Qualifying Therapeutic Discovery Project Program which was created in March 2010 as part of the Patient Protection and Affordability Care Act.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment, and Elestrin™ (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies. Additional information is available online at: www.biosantepharma.com.
For more information, please contact:
BioSante Pharmaceuticals
For Media:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Investors:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
BioSante incurred a net loss of approximately $11.6 million or ($0.16) per share for the quarter ended September 30, 2010, compared to a net loss of $6.4 million or ($0.21) per share for the same period in 2009. This increase in net loss was primarily due to increased LibiGel clinical development expenses.
The Company's cash and cash equivalents as of September 30, 2010 were approximately $35.5 million, as compared to cash and cash equivalents of approximately $29.9 million on December 31, 2009. In October 2010, the Company received $244,479, the maximum per project, after LibiGel qualified for a grant under the Qualifying Therapeutic Discovery Project Program which was created in March 2010 as part of the Patient Protection and Affordability Care Act.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment, and Elestrin™ (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies. Additional information is available online at: www.biosantepharma.com.
For more information, please contact:
BioSante Pharmaceuticals
For Media:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Investors:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
Visit the BPAX showcase profile at Investorideas.com
Request News and Info on BPAX
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com.
Request News and Info on BPAX
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com.
Friday, November 12, 2010
Biotech Stocks Trading Alert ; (OTCBB:UVFT), (NASDAQ:JAZZ), (OTCBB:AVXL) Stocks to Watch
Point Roberts, WA –November 12, 2010 (Investorideas.com Newswire and
www.biotechindustrystocks.com) - InvestorIdeas.com, a leader in sector research tools for
investors, features a Biotech /Pharma trading alert featuring Biotech stocks trading up in today’s
trading. With overall markets off, Spectrum Pharmaceuticals, Inc , Anavex Life Sciences Corp.,
and UV Flu Technologies Inc are trading in the green.
Biotech /Pharma Sector Trading Snapshot: (as of time of release November 12th)
UV Flu Technologies, Inc. (OTCBB: UVFT) trading at $0.2825, up 0.0025 (0.89%)
Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) trading at $4.58, up 0.16 (3.62%)
Anavex Life Sciences Corp. (OTCBB: AVXL) trading at $4.25, up 0.03 (0.71%)
Market Summary (at time of release)
Dow 11,178.39 -104.71 -0.93%
NASDAQ 2,518.20 -37.32 -1.46%
S&P 500 1,197.62 -15.92 -1.31%
10 Yr Bond(%) 2.7310% +0.0830
Oil 84.85 -2.96 -3.37%
Gold 1,362.50 -40.60 -2.89%
Biotech/Pharma Stocks Recent News;
UV Flu Technologies, Inc. (OTCBB: UVFT) News:
Biotech/Pharma Stocks News; UV Flu Technologies (OTCBB: UVFT) ViraTech UV-400
Featured This Weekend on Nationally Televised Designing Spaces "Holiday Spaces" Show
CENTERVILLE, MA – November 10, 2010 (Investorideas.com Newswire) - UV Flu Technologies,
Inc. (OTCBB: UVFT) (the "Company") is pleased to announce that the Company's ViraTech UV-
400 air purifier technology is featured during "Designing Spaces-Innovations for a Healthy Home
this Holiday Season," scheduled to air on Women's Entertainment (WeTV) this Friday, November
12th, at 9:30 am, EST, and again at the same hour on Sunday the 14th and Monday the 15th.
"I was very excited to participate on the show, particularly with Dr. Dennis Rosen, a Director
of our Company and one of the foremost Pediatricians in the country today, as well as a
real advocate for issues affecting children's health," said Jack Lennon, President of UV Flu
Technology. "We hope to educate the public on the dangers associated with poor indoor air
quality at every opportunity, as we believe it contributes to tens of thousands of deaths and
billions of dollars of health care and lost work expenditures every year. We also wanted to inform
and educate the public of the hazards posed though the use of existing filter based products on
the market today that can cause serious illness if the filters or the electrostatic plates are not
changed or cleaned on a constant basis."
Full Article: http://www.investorideas.com/CO/UVFT/news/11101.asp
About Anavex Life Sciences Corp, (OTCBB: AVXL):
Anavex Life Sciences Corp. (www.anavex.com) is a biopharmaceutical company engaged in the
discovery and development of novel drug candidates for the treatment of neurological diseases
and cancer. The company's proprietary SIGMACEPTOR(TM) Discovery Platform involves
the rational design of drug compounds that are targeted to specific receptors involved in the
modulation of multiple cellular biochemical signaling pathways.
ANAVEX's SIGMACEPTOR(TM)-N program involves the development of novel drug candidates
that target neurological and neurodegenerative diseases (Alzheimer's disease, epilepsy,
depression, pain). The company's lead drug candidates exhibit high affinity for sigma receptors,
which have been extensively documented as potentially valuable drug targets and have
demonstrated anti-amnesic and neuroprotective properties.
Anavex is a publically traded company under the symbol "AVXL".
About Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI):
Spectrum Pharmaceuticals is a biotechnology company with fully integrated commercial and
drug development operations with a primary focus in oncology. The Company’s strategy is
comprised of acquiring, developing and commercializing a broad and diverse pipeline of late-
stage clinical and commercial products. The Company markets two oncology drugs, FUSILEV
and ZEVALIN, and has two drugs, apaziquone and belinostat, in late stage development along
with a diversified pipeline of novel drug candidates. The Company has assembled an integrated
in-house scientific team, including clinical development, medical research, regulatory affairs,
biostatistics and data management, formulation development, and has established a commercial
infrastructure for the marketing of its drug products. The Company also leverages the expertise of
its worldwide partners to assist in the execution of its strategy. For more information, please visit
the Company’s website at www.sppirx.com.
Research other biotech stocks at the Biotech stocks Directory: http://
www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized
in sector investing, covering leading industry sectors including mining and gold stocks, in addition
to global markets including China, India, the Middle East and Australia. Investorideas.com is
known for its comprehensive stock directories in each sector and sector specific newswires
.
Sign up for free stock alerts on biotech stocks and other leading sectors!
http://www.investorideas.com/Resources/Newsletter.asp
More news - Visit the BPAX showcase profile at Investorideas.com
http://www.investorideas.com/CO/BPAX/
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com
About our Biotech investor portal:
www.BiotechIndustryStocks.com is a global meeting place for investors and industry following the
biotech and pharma sector, within Investorideas.com. Global visitors use the site daily to research
the latest news, articles, audio, research reports and our stock directories.
Disclaimer/disclosure : The following news is sponsored for by showcase stocks BPAX
(three thousand per month BPAX) Investorideas.com is a third party publisher of news and
research .Our sites do not make recommendations, but offer information portals to research
news, articles, stock lists and recent research. Nothing on our sites should be construed as an
offer or solicitation to buy or sell products or securities. All investment involves risk and possible
loss of principal. This site is currently compensated by featured companies, news submissions
and online advertising.
More info:
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
www.biotechindustrystocks.com) - InvestorIdeas.com, a leader in sector research tools for
investors, features a Biotech /Pharma trading alert featuring Biotech stocks trading up in today’s
trading. With overall markets off, Spectrum Pharmaceuticals, Inc , Anavex Life Sciences Corp.,
and UV Flu Technologies Inc are trading in the green.
Biotech /Pharma Sector Trading Snapshot: (as of time of release November 12th)
UV Flu Technologies, Inc. (OTCBB: UVFT) trading at $0.2825, up 0.0025 (0.89%)
Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) trading at $4.58, up 0.16 (3.62%)
Anavex Life Sciences Corp. (OTCBB: AVXL) trading at $4.25, up 0.03 (0.71%)
Market Summary (at time of release)
Dow 11,178.39 -104.71 -0.93%
NASDAQ 2,518.20 -37.32 -1.46%
S&P 500 1,197.62 -15.92 -1.31%
10 Yr Bond(%) 2.7310% +0.0830
Oil 84.85 -2.96 -3.37%
Gold 1,362.50 -40.60 -2.89%
Biotech/Pharma Stocks Recent News;
UV Flu Technologies, Inc. (OTCBB: UVFT) News:
Biotech/Pharma Stocks News; UV Flu Technologies (OTCBB: UVFT) ViraTech UV-400
Featured This Weekend on Nationally Televised Designing Spaces "Holiday Spaces" Show
CENTERVILLE, MA – November 10, 2010 (Investorideas.com Newswire) - UV Flu Technologies,
Inc. (OTCBB: UVFT) (the "Company") is pleased to announce that the Company's ViraTech UV-
400 air purifier technology is featured during "Designing Spaces-Innovations for a Healthy Home
this Holiday Season," scheduled to air on Women's Entertainment (WeTV) this Friday, November
12th, at 9:30 am, EST, and again at the same hour on Sunday the 14th and Monday the 15th.
"I was very excited to participate on the show, particularly with Dr. Dennis Rosen, a Director
of our Company and one of the foremost Pediatricians in the country today, as well as a
real advocate for issues affecting children's health," said Jack Lennon, President of UV Flu
Technology. "We hope to educate the public on the dangers associated with poor indoor air
quality at every opportunity, as we believe it contributes to tens of thousands of deaths and
billions of dollars of health care and lost work expenditures every year. We also wanted to inform
and educate the public of the hazards posed though the use of existing filter based products on
the market today that can cause serious illness if the filters or the electrostatic plates are not
changed or cleaned on a constant basis."
Full Article: http://www.investorideas.com/CO/UVFT/news/11101.asp
About Anavex Life Sciences Corp, (OTCBB: AVXL):
Anavex Life Sciences Corp. (www.anavex.com) is a biopharmaceutical company engaged in the
discovery and development of novel drug candidates for the treatment of neurological diseases
and cancer. The company's proprietary SIGMACEPTOR(TM) Discovery Platform involves
the rational design of drug compounds that are targeted to specific receptors involved in the
modulation of multiple cellular biochemical signaling pathways.
ANAVEX's SIGMACEPTOR(TM)-N program involves the development of novel drug candidates
that target neurological and neurodegenerative diseases (Alzheimer's disease, epilepsy,
depression, pain). The company's lead drug candidates exhibit high affinity for sigma receptors,
which have been extensively documented as potentially valuable drug targets and have
demonstrated anti-amnesic and neuroprotective properties.
Anavex is a publically traded company under the symbol "AVXL".
About Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI):
Spectrum Pharmaceuticals is a biotechnology company with fully integrated commercial and
drug development operations with a primary focus in oncology. The Company’s strategy is
comprised of acquiring, developing and commercializing a broad and diverse pipeline of late-
stage clinical and commercial products. The Company markets two oncology drugs, FUSILEV
and ZEVALIN, and has two drugs, apaziquone and belinostat, in late stage development along
with a diversified pipeline of novel drug candidates. The Company has assembled an integrated
in-house scientific team, including clinical development, medical research, regulatory affairs,
biostatistics and data management, formulation development, and has established a commercial
infrastructure for the marketing of its drug products. The Company also leverages the expertise of
its worldwide partners to assist in the execution of its strategy. For more information, please visit
the Company’s website at www.sppirx.com.
Research other biotech stocks at the Biotech stocks Directory: http://
www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized
in sector investing, covering leading industry sectors including mining and gold stocks, in addition
to global markets including China, India, the Middle East and Australia. Investorideas.com is
known for its comprehensive stock directories in each sector and sector specific newswires
.
Sign up for free stock alerts on biotech stocks and other leading sectors!
http://www.investorideas.com/Resources/Newsletter.asp
More news - Visit the BPAX showcase profile at Investorideas.com
http://www.investorideas.com/CO/BPAX/
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com
About our Biotech investor portal:
www.BiotechIndustryStocks.com is a global meeting place for investors and industry following the
biotech and pharma sector, within Investorideas.com. Global visitors use the site daily to research
the latest news, articles, audio, research reports and our stock directories.
Disclaimer/disclosure : The following news is sponsored for by showcase stocks BPAX
(three thousand per month BPAX) Investorideas.com is a third party publisher of news and
research .Our sites do not make recommendations, but offer information portals to research
news, articles, stock lists and recent research. Nothing on our sites should be construed as an
offer or solicitation to buy or sell products or securities. All investment involves risk and possible
loss of principal. This site is currently compensated by featured companies, news submissions
and online advertising.
More info:
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
NASDAQ Biotech/Pharma Stock Watch ; (NASDAQ:BPAX), (NASDAQ:MNKD), (NASDAQ:SPPI)
Point Roberts, WA –November 12, 2010 (Investorideas.com Newswire and
www.biotechindustrystocks.com) - InvestorIdeas.com, a leader in sector research tools
for investors, features a Biotech /Pharma Sector Trading Snapshot featuring some of the
NASDAQ’s market performers for the week. In todays down markets, Spectrum Pharmaceuticals,
Inc and Jazz Pharmaceuticals, Inc are in the green.
Biotech /Pharma Sector Trading Snapshot: (as of time of release November 12th)
Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) trading at $4.5899, up 0.1699 (3.84%)
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) trading at $1.56
Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) trading at $ 15.15, up 0.03 (0.20%)
Market Summary (at time of release)
Dow 11,172.60 -110.50 -0.98%
NASDAQ 2,515.66 -39.86 -1.56%
S&P 500 1,197.46 -16.08 -1.33%
10 Yr Bond (%) 2.7450% +0.0970
Oil 84.89 -2.92 -3.33%
Gold 1,387.70 -15.40 -1.10%
Biotech/Pharma Stocks Recent News;
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) News:
Investor Spotlight on BioSante Pharmaceuticals (NASDAQ: BPAX) Lead Product LibiGel® -
testosterone gel for the treatment of female sexual dysfunction
Market for LibiGel® has wide potential with predictions ranging from about $2.0 billion up
to $5 billion
Point Roberts, WA, LINCOLNSHIRE, Ill –November 9, 2010 (Investorideas.com Newswire,)
Investor ideas and its biotech portal present a company and product spotlight for BioSante
Pharmaceuticals, Inc. (NASDAQ: BPAX) lead product LibiGel®.
Investors following biotech and pharmaceutical stocks can take an in-depth look at the current
status of LibiGel®, the clinical data, the market drivers and opportunities within the company
product brochure, recent news links and a recent Q&A with Mr. Stephen M. Simes, President and
CEO discussing LibiGel.
Highlights from the LibiGel Brochure:
Read the Full Brochure at: http://www.biosantepharma.com/libigel/LibiGel-Brochure.pdf
LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who
suffer from female sexual dysfunction (FSD). The on-going Phase III efficacy trials are double-
blind, placebo-controlled trials that will enroll up to approximately 500 surgically menopausal
women each for a six-month clinical trial. The efficacy trials are being conducted under an FDA-
approved special protocol assessment (SPA) agreement. LibiGel is absorbed quickly through
the skin after applying a once-daily pea-sized topical application on the upper arm that delivers
testosterone to the bloodstream evenly over time.
Full Article: http://www.investorideas.com/CO/BPAX/news/11101.asp
Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) News:
“Jazz Pharmaceuticals, Inc. announced today that Bruce Cozadd, the company's chairman and
chief executive officer, will present at the Lazard Capital Markets Healthcare Conference in New
York on Wednesday, November 17, 2010 at 9:00 a.m. Eastern Time.
A live webcast of the presentation may be accessed from the Investors section of the Jazz
Pharmaceuticals website at www.jazzpharmaceuticals.com. Please connect to the website prior
to the start of the conference call to ensure adequate time for any software downloads that may
be necessary to listen to the webcast.”
Full Article: http://finance.yahoo.com/news/Jazz-Pharmaceuticals-prnews-
3715707836.html?x=0&.v=1
About Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ):
Jazz Pharmaceuticals is a specialty pharmaceutical company that identifies, develops and
commercializes innovative treatments for important, underserved markets in neurology and
psychiatry. For further information see www.jazzpharmaceuticals.com.
About Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI):
Spectrum Pharmaceuticals is a biotechnology company with fully integrated commercial and
drug development operations with a primary focus in oncology. The Company’s strategy is
comprised of acquiring, developing and commercializing a broad and diverse pipeline of late-
stage clinical and commercial products. The Company markets two oncology drugs, FUSILEV
and ZEVALIN, and has two drugs, apaziquone and belinostat, in late stage development along
with a diversified pipeline of novel drug candidates. The Company has assembled an integrated
in-house scientific team, including clinical development, medical research, regulatory affairs,
biostatistics and data management, formulation development, and has established a commercial
infrastructure for the marketing of its drug products. The Company also leverages the expertise of
its worldwide partners to assist in the execution of its strategy. For more information, please visit
the Company’s website at www.sppirx.com.
Research other biotech stocks at the Biotech stocks Directory: http://
www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized
in sector investing, covering leading industry sectors including mining and gold stocks, in addition
to global markets including China, India, the Middle East and Australia. Investorideas.com is
known for its comprehensive stock directories in each sector and sector specific newswires
.
Sign up for free stock alerts on biotech stocks and other leading sectors!
http://www.investorideas.com/Resources/Newsletter.asp
More news - Visit the BPAX showcase profile at Investorideas.com
http://www.investorideas.com/CO/BPAX/
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com
About our Biotech investor portal:
www.BiotechIndustryStocks.com is a global meeting place for investors and industry following the
biotech and pharma sector, within Investorideas.com. Global visitors use the site daily to research
the latest news, articles, audio, research reports and our stock directories.
Disclaimer/disclosure : The following news is sponsored for by showcase stocks BPAX
(three thousand per month BPAX) Investorideas.com is a third party publisher of news and
research .Our sites do not make recommendations, but offer information portals to research
news, articles, stock lists and recent research. Nothing on our sites should be construed as an
offer or solicitation to buy or sell products or securities. All investment involves risk and possible
loss of principal. This site is currently compensated by featured companies, news submissions
and online advertising.
More info:
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
www.biotechindustrystocks.com) - InvestorIdeas.com, a leader in sector research tools
for investors, features a Biotech /Pharma Sector Trading Snapshot featuring some of the
NASDAQ’s market performers for the week. In todays down markets, Spectrum Pharmaceuticals,
Inc and Jazz Pharmaceuticals, Inc are in the green.
Biotech /Pharma Sector Trading Snapshot: (as of time of release November 12th)
Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) trading at $4.5899, up 0.1699 (3.84%)
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) trading at $1.56
Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) trading at $ 15.15, up 0.03 (0.20%)
Market Summary (at time of release)
Dow 11,172.60 -110.50 -0.98%
NASDAQ 2,515.66 -39.86 -1.56%
S&P 500 1,197.46 -16.08 -1.33%
10 Yr Bond (%) 2.7450% +0.0970
Oil 84.89 -2.92 -3.33%
Gold 1,387.70 -15.40 -1.10%
Biotech/Pharma Stocks Recent News;
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) News:
Investor Spotlight on BioSante Pharmaceuticals (NASDAQ: BPAX) Lead Product LibiGel® -
testosterone gel for the treatment of female sexual dysfunction
Market for LibiGel® has wide potential with predictions ranging from about $2.0 billion up
to $5 billion
Point Roberts, WA, LINCOLNSHIRE, Ill –November 9, 2010 (Investorideas.com Newswire,)
Investor ideas and its biotech portal present a company and product spotlight for BioSante
Pharmaceuticals, Inc. (NASDAQ: BPAX) lead product LibiGel®.
Investors following biotech and pharmaceutical stocks can take an in-depth look at the current
status of LibiGel®, the clinical data, the market drivers and opportunities within the company
product brochure, recent news links and a recent Q&A with Mr. Stephen M. Simes, President and
CEO discussing LibiGel.
Highlights from the LibiGel Brochure:
Read the Full Brochure at: http://www.biosantepharma.com/libigel/LibiGel-Brochure.pdf
LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who
suffer from female sexual dysfunction (FSD). The on-going Phase III efficacy trials are double-
blind, placebo-controlled trials that will enroll up to approximately 500 surgically menopausal
women each for a six-month clinical trial. The efficacy trials are being conducted under an FDA-
approved special protocol assessment (SPA) agreement. LibiGel is absorbed quickly through
the skin after applying a once-daily pea-sized topical application on the upper arm that delivers
testosterone to the bloodstream evenly over time.
Full Article: http://www.investorideas.com/CO/BPAX/news/11101.asp
Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) News:
“Jazz Pharmaceuticals, Inc. announced today that Bruce Cozadd, the company's chairman and
chief executive officer, will present at the Lazard Capital Markets Healthcare Conference in New
York on Wednesday, November 17, 2010 at 9:00 a.m. Eastern Time.
A live webcast of the presentation may be accessed from the Investors section of the Jazz
Pharmaceuticals website at www.jazzpharmaceuticals.com. Please connect to the website prior
to the start of the conference call to ensure adequate time for any software downloads that may
be necessary to listen to the webcast.”
Full Article: http://finance.yahoo.com/news/Jazz-Pharmaceuticals-prnews-
3715707836.html?x=0&.v=1
About Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ):
Jazz Pharmaceuticals is a specialty pharmaceutical company that identifies, develops and
commercializes innovative treatments for important, underserved markets in neurology and
psychiatry. For further information see www.jazzpharmaceuticals.com.
About Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI):
Spectrum Pharmaceuticals is a biotechnology company with fully integrated commercial and
drug development operations with a primary focus in oncology. The Company’s strategy is
comprised of acquiring, developing and commercializing a broad and diverse pipeline of late-
stage clinical and commercial products. The Company markets two oncology drugs, FUSILEV
and ZEVALIN, and has two drugs, apaziquone and belinostat, in late stage development along
with a diversified pipeline of novel drug candidates. The Company has assembled an integrated
in-house scientific team, including clinical development, medical research, regulatory affairs,
biostatistics and data management, formulation development, and has established a commercial
infrastructure for the marketing of its drug products. The Company also leverages the expertise of
its worldwide partners to assist in the execution of its strategy. For more information, please visit
the Company’s website at www.sppirx.com.
Research other biotech stocks at the Biotech stocks Directory: http://
www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized
in sector investing, covering leading industry sectors including mining and gold stocks, in addition
to global markets including China, India, the Middle East and Australia. Investorideas.com is
known for its comprehensive stock directories in each sector and sector specific newswires
.
Sign up for free stock alerts on biotech stocks and other leading sectors!
http://www.investorideas.com/Resources/Newsletter.asp
More news - Visit the BPAX showcase profile at Investorideas.com
http://www.investorideas.com/CO/BPAX/
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com
About our Biotech investor portal:
www.BiotechIndustryStocks.com is a global meeting place for investors and industry following the
biotech and pharma sector, within Investorideas.com. Global visitors use the site daily to research
the latest news, articles, audio, research reports and our stock directories.
Disclaimer/disclosure : The following news is sponsored for by showcase stocks BPAX
(three thousand per month BPAX) Investorideas.com is a third party publisher of news and
research .Our sites do not make recommendations, but offer information portals to research
news, articles, stock lists and recent research. Nothing on our sites should be construed as an
offer or solicitation to buy or sell products or securities. All investment involves risk and possible
loss of principal. This site is currently compensated by featured companies, news submissions
and online advertising.
More info:
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
Thursday, November 11, 2010
Biotech Stock Trading Alert; UV Flu Technologies (OTCBB: UVFT) Trading up on News
Point Roberts, WA. – November 11, 2010 (Investorideas.com Newswire) - www.InvestorIdeas.com and its leading Biotech investor portal, announces a technical stock trading alert and stock chart for showcase Biotech company UV Flu Technologies (OTCBB: UVFT).
Stock Chart for UVFT.OB
Recent News:
Biotech/Pharma Stocks News; UV Flu Technologies (OTCBB: UVFT) Announces UV-400 Air Purifier Delivers Favorable Preliminary Test Results for the Inactivation of Viruses
CENTERVILLE, MA – November 11, 2010 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce that the Company has received favorable preliminary test results from an independent, FDA and EPA certified test facility that demonstrated the ViraTech UV-400 air purifier to be effective in the inactivation of a typical virus surrogate utilized as part of the test protocol.
"These results, although preliminary, are highly encouraging," said Jack Lennon, President of UV Flu Technologies. "The viral phage was tested multiple times, with the UV-400 running at three different speeds; low, medium and high, over a four hour period in a 430 cubic foot test chamber. After three hours, the chamber showed a sample inactivation rate of at least 99% over all three speeds, which was shown to be even higher at the four hour mark. We must emphasize that these results, although very positive, are only preliminary, but appear comparable to our previous results during the laboratory testing of the inactivation of bacteria. Our Company is firmly committed to supporting all claims with actual, verifiable laboratory testing undertaken by reputable agencies within certified facilities." More: http://www.investorideas.com/CO/UVFT/news/11111.asp
About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies, Inc. (OTCBB: UVFT) is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. VIRATECH UV-400 is a Class II medical device and is available.
Investors can view the full company profile for UV Flu Technologies, Inc. (UVFT.OB) at: http://www.investorideas.com/CO/UVFT/
Research Report by Michael Williams, Biotech Stock Pick: www.biotechstockpick.com
Find out more about UV Flu Technologies, Inc. (UVFT.OB) at: www.uvflutech.com
Request news and stock alerts from UV Flu Technologies, Inc. (UVFT.OB)
http://www.investorideas.com/Resources/Newsletter.asp
Contact UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
About our Biotech investor portal: www.biotechindustrystocks.com
BiotechIndustryStocks.com is a global meeting place for investors and industry following the sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
http://www.investorideas.com/BIS/Stock_List.asp
Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc., (three thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of principal. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
For Additional Information about Investorideas.com energy portals: 800-665-0411 or cvanzant@investorideas.com
Stock Chart for UVFT.OB
Recent News:Biotech/Pharma Stocks News; UV Flu Technologies (OTCBB: UVFT) Announces UV-400 Air Purifier Delivers Favorable Preliminary Test Results for the Inactivation of Viruses
CENTERVILLE, MA – November 11, 2010 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce that the Company has received favorable preliminary test results from an independent, FDA and EPA certified test facility that demonstrated the ViraTech UV-400 air purifier to be effective in the inactivation of a typical virus surrogate utilized as part of the test protocol.
"These results, although preliminary, are highly encouraging," said Jack Lennon, President of UV Flu Technologies. "The viral phage was tested multiple times, with the UV-400 running at three different speeds; low, medium and high, over a four hour period in a 430 cubic foot test chamber. After three hours, the chamber showed a sample inactivation rate of at least 99% over all three speeds, which was shown to be even higher at the four hour mark. We must emphasize that these results, although very positive, are only preliminary, but appear comparable to our previous results during the laboratory testing of the inactivation of bacteria. Our Company is firmly committed to supporting all claims with actual, verifiable laboratory testing undertaken by reputable agencies within certified facilities." More: http://www.investorideas.com/CO/UVFT/news/11111.asp
About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies, Inc. (OTCBB: UVFT) is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. VIRATECH UV-400 is a Class II medical device and is available.
Investors can view the full company profile for UV Flu Technologies, Inc. (UVFT.OB) at: http://www.investorideas.com/CO/UVFT/
Research Report by Michael Williams, Biotech Stock Pick: www.biotechstockpick.com
Find out more about UV Flu Technologies, Inc. (UVFT.OB) at: www.uvflutech.com
Request news and stock alerts from UV Flu Technologies, Inc. (UVFT.OB)
http://www.investorideas.com/Resources/Newsletter.asp
Contact UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
About our Biotech investor portal: www.biotechindustrystocks.com
BiotechIndustryStocks.com is a global meeting place for investors and industry following the sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Sign up for the free investor news letter and get stock alerts in leading sectors! http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory:http://www.investorideas.com/BIS/Stock_List.asp
Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc., (three thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of principal. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
For Additional Information about Investorideas.com energy portals: 800-665-0411 or cvanzant@investorideas.com
Biotech/Pharma Stocks News; UV Flu Technologies (OTCBB: UVFT) Announces UV-400 Air Purifier Delivers Favorable Preliminary Test Results for the Inactivation of Viruses
CENTERVILLE, MA � November 11, 2010 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce that the Company has received favorable preliminary test results from an independent, FDA and EPA certified test facility that demonstrated the ViraTech UV-400 air purifier to be effective in the inactivation of a typical virus surrogate utilized as part of the test protocol.
"These results, although preliminary, are highly encouraging," said Jack Lennon, President of UV Flu Technologies. "The viral phage was tested multiple times, with the UV-400 running at three different speeds; low, medium and high, over a four hour period in a 430 cubic foot test chamber. After three hours, the chamber showed a sample inactivation rate of at least 99% over all three speeds, which was shown to be even higher at the four hour mark. We must emphasize that these results, although very positive, are only preliminary, but appear comparable to our previous results during the laboratory testing of the inactivation of bacteria. Our Company is firmly committed to supporting all claims with actual, verifiable laboratory testing undertaken by reputable agencies within certified facilities."
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Request info:
http://www.investorideas.com/Resources/Newsletter.asp
"These results, although preliminary, are highly encouraging," said Jack Lennon, President of UV Flu Technologies. "The viral phage was tested multiple times, with the UV-400 running at three different speeds; low, medium and high, over a four hour period in a 430 cubic foot test chamber. After three hours, the chamber showed a sample inactivation rate of at least 99% over all three speeds, which was shown to be even higher at the four hour mark. We must emphasize that these results, although very positive, are only preliminary, but appear comparable to our previous results during the laboratory testing of the inactivation of bacteria. Our Company is firmly committed to supporting all claims with actual, verifiable laboratory testing undertaken by reputable agencies within certified facilities."
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Request info:
http://www.investorideas.com/Resources/Newsletter.asp
Subscribe to:
Posts (Atom)